Updated Jul 16, 2026
Kuriakose Emil has filed 1 SEC Form 4 filing across 1 company in the last 90 days — selling. Lifetime open-market sales: $61K.
Emil Kuriakose is the Chief Medical Officer at Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing therapies for chronic liver diseases. He has been involved in the company's SEC filings, indicating his role in the organization.
| Role | Insider |
|---|---|
| Notability | 20/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-05 | TERN | Terns Pharmaceuticals, Inc. | D — Derivative transaction | 82.0K | $53.00 | $4.34M |
| 2026-05-05 | TERN | Terns Pharmaceuticals, Inc. | J — Other acquisition / disposition | 24.6K | $53.00 | $1.30M |
| 2026-04-02 | TERN | Terns Pharmaceuticals, Inc. | S — Open-market sale | 942 | $52.75 | $50K |
| 2026-01-16 | TERN | Terns Pharmaceuticals, Inc. | A — Grant or award | 56.2K | $0.00 | |
| 2025-10-01 | TERN | Terns Pharmaceuticals, Inc. | S — Open-market sale | 944 | $7.85 | $7K |
| 2025-07-01 | TERN | Terns Pharmaceuticals, Inc. | S — Open-market sale | 853 | $4.27 | $4K |
Emil Kuriakose is the Chief Medical Officer at Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing therapies for chronic liver diseases. He has been involved in the company's SEC filings, indicating his role in the organization.…
1 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 3 open-market sales ($61K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Kuriakose Emil profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.